{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T23:57:16Z","timestamp":1772927836800,"version":"3.50.1"},"reference-count":98,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100004320","name":"Research Council of Shiraz University of Medical Sciences, Shiraz, Iran","doi-asserted-by":"publisher","award":["IR.SUMS.REC.1400.562"],"award-info":[{"award-number":["IR.SUMS.REC.1400.562"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["BIOT"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Immune thrombocytopenic purpura (ITP) is an autoimmune disorder determined\nby immune-mediated platelet demolition and reduction of platelet production. Romiplostim\nis a new thrombopoiesis motivating peptibody that binds and stimulates the human thrombopoietin\nreceptor the patent of which was registered in 2008. It is used to treat thrombocytopenia\nin patients with chronic immune thrombocytopenic purpura. Romiplostim is a 60\nkDa peptibody designed to inhibit cross-reacting immune responses. It consists of four\nhigh-affinity TPO-receptor binding domains for the Mpl receptor and one human IgG1 Fc\ndomain. Escherichia coli is a good host for the fabrication of recombinant proteins such as\nromiplostim. The expression of a gene intended in E. coli is dependent on many factors\nsuch as a protein\u2019s inherent ability to fold, mRNA\u2019s secondary structure, its solubility, its\ntoxicity preferential codon use, and its need for post-translational modification (PTM).\nThis review focuses on the structure, function, mechanism of action, and expressive approach\nto romiplostim in E. coli.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1872208317666230503094451","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T10:20:49Z","timestamp":1685960449000},"page":"95-109","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Review on Romiplostim Mechanism of Action and the Expressive\nApproach in E. coli"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-0816","authenticated-orcid":true,"given":"Masoud","family":"Hashemzaei","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Bagher","family":"Ghoshoon","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrnaz","family":"Jamshidi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Moradbeygi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Hashemzehi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1690","volume":"3","author":"Patel H.","year":"2009","unstructured":"Patel H.; Patel N.; Vyas A.; Patel M.; Pandey S.; Romiplostim: A novel c-Mpl\/CD110 receptor ligand for the management of idiopathic thrombocytopenic purpura. J Clin Diagn Res 2009,3(4),1690-1696","journal-title":"J Clin Diagn Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1182\/blood-2012-03-410415","volume":"119","author":"Lambert M.P.","year":"2012","unstructured":"Lambert M.P.; Platelets and eltrombopag: A not-so-sticky situation. Blood 2012,119(17),3876-3877","journal-title":"Blood"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"100811","DOI":"10.1016\/j.blre.2021.100811","volume":"49","author":"Kuter D.J.","year":"2021","unstructured":"Kuter D.J.; Tarantino M.D.; Lawrence T.; Clinical overview and practical considerations for optimizing romiplostim thera-py in patients with immune thrombocytopenia. Blood Rev 2021,49,100811","journal-title":"Blood Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2141.2010.08140.x","volume":"150","author":"Molineux G.","year":"2010","unstructured":"Molineux G.; Newland A.; Development of romiplostim for the treatment of patients with chronic immune thrombocyto-penia: From bench to bedside. Br J Haematol 2010,150(1),9-20","journal-title":"Br J Haematol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","volume":"371","author":"Kuter D.J.","year":"2008","unstructured":"Kuter D.J.; Bussel J.B.; Lyons R.M.; Efficacy of romiplostim in patients with chronic immune thrombocytopenic pur-pura: A double-blind randomised controlled trial. Lancet 2008,371(9610),395-403","journal-title":"Lancet"},{"key":"ref=6","author":"Liu C-F","year":"2006","unstructured":"Liu C-F; Feige U; Cheetham JC;  Thrombopoietic compounds 2006","journal-title":"Thrombopoietic compounds"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pep.2008.01.008","volume":"59","author":"Burgess-Brown N.A.","year":"2008","unstructured":"Burgess-Brown N.A.; Sharma S.; Sobott F.; Loenarz C.; Oppermann U.; Gileadi O.; Codon optimization can improve expres-sion of human genes in Escherichia coli: A multi-gene study. Protein Expr Purif 2008,59(1),94-102","journal-title":"Protein Expr Purif"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1128\/mr.60.3.512-538.1996","volume":"60","author":"Makrides S.C.","year":"1996","unstructured":"Makrides S.C.; Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol Rev 1996,60(3),512-538","journal-title":"Microbiol Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10930-013-9502-5","volume":"32","author":"Gopal G.J.","year":"2013","unstructured":"Gopal G.J.; Kumar A.; Strategies for the production of recombinant protein in Escherichia coli. Protein J 2013,32(6),419-425","journal-title":"Protein J"},{"key":"ref=10","first-page":"493","volume":"11","author":"Redwan E.","year":"2006","unstructured":"Redwan E.; The optimal gene sequence for optimal protein expression in Escherichia coli: Principle requirements. Arab J Biotechnol 2006,11(1),493-510","journal-title":"Arab J Biotechnol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.V82.5.1395.1395","volume":"82","author":"Methia N.","year":"1993","unstructured":"Methia N.; Louache F.; Vainchenker W.; Wendling F.; Oligodeoxynucleotides antisense to the proto-oncogene c-mpl spe-cifically inhibit in vitro megakaryocytopoiesis. Blood 1993,82(5),1395-1401","journal-title":"Blood"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1177\/0091270011420843","volume":"52","author":"Perez-Ruixo J.J.","year":"2012","unstructured":"Perez-Ruixo J.J.; Green B.; Doshi S.; Wang Y.M.; Mould D.R.; Romiplostim dose response in patients with immune thrombo-cytopenia. J Clin Pharmacol 2012,52(10),1540-1551","journal-title":"J Clin Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1073\/pnas.92.8.3234","volume":"92","author":"Kaushansky K.","year":"1995","unstructured":"Kaushansky K.; Broudy V.C.; Lin N.; Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte develop-ment. Proc Natl Acad Sci 1995,92(8),3234-3238","journal-title":"Proc Natl Acad Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","volume":"100","author":"Kuter D.J.","year":"2002","unstructured":"Kuter D.J.; Begley C.G.; Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies. Blood 2002,100(10),3457-3469","journal-title":"Blood"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1182\/blood.V90.9.3423","volume":"90","author":"Bunting S.","year":"1997","unstructured":"Bunting S.; Widmer R.; Lipari T.; Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood 1997,90(9),3423-3429","journal-title":"Blood"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1182\/blood.V86.12.4486.bloodjournal86124486","volume":"86","author":"Hokom M.M.","year":"1995","unstructured":"Hokom M.M.; Lacey D.; Kinstler O.B.; Choi E.; Kaufman S.; Faust J.; Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995,86(12),4486-4492","journal-title":"Blood"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","volume":"88","author":"George J.N.","year":"1996","unstructured":"George J.N.; Woolf S.H.; Raskob G.E.; Idiopathic thrombocytopenic purpura: A practice guideline developed by ex-plicit methods for the American Society of Hematology. Blood 1996,88(1),3-40","journal-title":"Blood"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1046\/j.1365-2141.2003.04131.x","volume":"120","year":"2003","unstructured":"British Committee for Standards in Haematology General Haematology Task Force Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003,120(4),574-596","journal-title":"Br J Haematol"},{"key":"ref=19","first-page":"356","volume":"64","author":"Stevens W.","year":"2006","unstructured":"Stevens W.; Koene H.; Zwaginga J.J.; Vreugdenhil G.; Chronic idiopathic thrombocytopenic purpura: Present strategy, guidelines and new insights. Neth J Med 2006,64(10),356-363","journal-title":"Neth J Med"},{"key":"ref=20","first-page":"36","volume":"35","author":"Blanchette V.","year":"1998","unstructured":"Blanchette V.; Freedman J.; Garvey B.; Eds., Management of chronic immune thrombocytopenic purpura in children and adults. Semin Hematol 1998,35(S1),36-51","journal-title":"Semin Hematol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0140-6736(02)07275-6","volume":"359","author":"Godeau B.","year":"2002","unstructured":"Godeau B.; Chevret S.; Varet B.; Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomised, multicentre trial. Lancet 2002,359(9300),23-29","journal-title":"Lancet"},{"key":"ref=22","author":"Stasi R.","year":"2004","unstructured":"Stasi R.; Provan D.;  Management of immune thrombocytopenic purpura in adults Mayo Clinic Proceedings 2004","journal-title":"Management of immune thrombocytopenic purpura in adults Mayo Clinic Proceedings"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","volume":"104","author":"Kojouri K.","year":"2004","unstructured":"Kojouri K.; Vesely S.K.; Terrell D.R.; George J.N.; Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004,104(9),2623-2634","journal-title":"Blood"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1160\/TH07-08-0513","volume":"99","author":"Evangelista M.L.","year":"2008","unstructured":"Evangelista M.L.; Stipa E.; Buccisano F.; Venditti A.; Amadori S.; Stasi R.; Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thromb Haemost 2008,99(1),4-13","journal-title":"Thromb Haemost"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7326\/0003-4819-140-3-200402030-00012","volume":"140","author":"Vesely S.K.","year":"2004","unstructured":"Vesely S.K.; Perdue J.J.; Rizvi M.A.; Terrell D.R.; George J.N.; Management of adult patients with persistent idiopathic throm-bocytopenic purpura following splenectomy: A systematic review. Ann Intern Med 2004,140(2),112-120","journal-title":"Ann Intern Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd2741","volume":"7","author":"Cines D.B.","year":"2008","unstructured":"Cines D.B.; Yasothan U.; Kirkpatrick P.; Romiplostim. Nat Rev Drug Discov 2008,7(11),887-888","journal-title":"Nat Rev Drug Discov"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1172\/JCI113060","volume":"80","author":"Ballem P.J.","year":"1987","unstructured":"Ballem P.J.; Segal G.M.; Stratton J.R.; Gernsheimer T.; Adamson J.W.; Slichter S.J.; Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987,80(1),33-40","journal-title":"J Clin Invest"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2007-05-088500","volume":"111","author":"Kaushansky K.","year":"2008","unstructured":"Kaushansky K.; Historical review: Megakaryopoiesis and thrombopoiesis. Blood 2008,111(3),981-986","journal-title":"Blood"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/blood.V100.2.728","volume":"100","author":"Nomura S.","year":"2002","unstructured":"Nomura S.; Dan K.; Hotta T.; Fujimura K.; Ikeda Y.; Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002,100(2),728-730","journal-title":"Blood"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","volume":"98","author":"Li J.","year":"2001","unstructured":"Li J.; Yang C.; Xia Y.; Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001,98(12),3241-3248","journal-title":"Blood"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.drudis.2008.06.002","volume":"13","author":"Peeters K.","year":"2008","unstructured":"Peeters K.; Stassen J.M.; Collen D.; Van Geet C.; Freson K.; Emerging treatments for thrombocytopenia: Increasing platelet production. Drug Discov Today 2008,13(17-18),798-806","journal-title":"Drug Discov Today"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","volume":"76","author":"Wang B.","year":"2004","unstructured":"Wang B.; Nichol J.; Sullivan J.; Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004,76(6),628-638","journal-title":"Clin Pharmacol Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1600-0609.2007.00999.x","volume":"80","author":"Kuter D.J.","year":"2008","unstructured":"Kuter D.J.; New drugs for familiar therapeutic targets: Thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol 2008,80(69),9-18","journal-title":"Eur J Haematol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","volume":"109","author":"Kuter D.J.","year":"2007","unstructured":"Kuter D.J.; New thrombopoietic growth factors. Blood 2007,109(11),4607-4616","journal-title":"Blood"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1056\/NEJM199809103391107","volume":"339","author":"Kaushansky K.","year":"1998","unstructured":"Kaushansky K.; Thrombopoietin KK.;  N Engl J Med 1998,339(11),746-754","journal-title":"N Engl J Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06339.x","volume":"135","author":"Newland A.","year":"2006","unstructured":"Newland A.; Caulier M.T.; Kappers-Klunne M.; An open-label, unit dose-finding study of AMG 531, a novel throm-bopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006,135(4),547-553","journal-title":"Br J Haematol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa054626","volume":"355","author":"Bussel J.B.","year":"2006","unstructured":"Bussel J.B.; Kuter D.J.; George J.N.; AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006,355(16),1672-1681","journal-title":"N Engl J Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cyto.2003.05.001","volume":"25","author":"Broudy V.","year":"2004","unstructured":"Broudy V.; Lin N.L.; AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004,25(2),52-60","journal-title":"Cytokine"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/MOH.0b013e3282b9748f","volume":"14","author":"Godeau B.","year":"2007","unstructured":"Godeau B.; Provan D.; Bussel J.; Immune thrombocytopenic purpura in adults. Curr Opin Hematol 2007,14(5),535-556","journal-title":"Curr Opin Hematol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/pbc.20972","volume":"47","author":"Nichol J.L.","year":"2006","unstructured":"Nichol J.L.; AMG 531: An investigational thrombopoiesis-stimulating peptibody. Pediatr Blood Cancer 2006,47(S5),723-725","journal-title":"Pediatr Blood Cancer"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1177\/0091270007306563","volume":"47","author":"Kumagai Y.","year":"2007","unstructured":"Kumagai Y.; Fujita T.; Ozaki M.; Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: A randomized, placebo-controlled study. J Clin Pharmacol 2007,47(12),1489-1497","journal-title":"J Clin Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2165\/00003495-200969030-00006","volume":"69","author":"Frampton J.E.","year":"2009","unstructured":"Frampton J.E.; Lyseng-Williamson K.A.; Romiplostim. Drugs 2009,69(3),307-317","journal-title":"Drugs"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12288-021-01431-y","volume":"38","author":"Singh I.","year":"2022","unstructured":"Singh I.; Swetha R.K.; Patel R.; Pharmacokinetics, pharmacodynamics, efficacy and safety of a romiplostim biosim-ilar in chronic refractory immune thrombocytopenic purpura (ITP) patients. Indian J Hematol Blood Transfus 2022,38(1),111-121","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref=44","year":"2008","unstructured":"Nplate (Romiplostim) public assessment report. European\tMedicines Agency Evaluation of Medicines\tfor Human Use. Available from:\n2008"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood.V112.11.402.402","volume":"112","author":"Kuter D.J.","year":"2008","unstructured":"Kuter D.J.; Bussel J.B.; Newland A.; Long-term treatment with romiplostim in patients with chronic immune thrombo-cytopenic purpura (ITP): 3-year update from an open-label extension study. Blood 2008,112(11),402","journal-title":"Blood"},{"key":"ref=46","first-page":"267","author":"Kuter D.J.","year":"2010","unstructured":"Kuter D.J.;  Romiplostim In: Hematopoietic Growth\tFactors in Oncology 2010,267-88","journal-title":"Romiplostim In: Hematopoietic Growth\tFactors in Oncology"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2165\/11208260-000000000-00000","volume":"72","author":"Keating G.M.","year":"2012","unstructured":"Keating G.M.; Romiplostim. Drugs 2012,72(3),415-435","journal-title":"Drugs"},{"key":"ref=48","author":"Tridente G.","year":"2013","unstructured":"Tridente G.;  Adverse Events of Biomedicines 2013","journal-title":"Adverse Events of Biomedicines"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/0958-1669(95)80082-4","volume":"6","author":"Kane J.F.","year":"1995","unstructured":"Kane J.F.; Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr Opin Biotechnol 1995,6(5),494-500","journal-title":"Curr Opin Biotechnol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1093\/nar\/20.24.6707","volume":"20","author":"Kane J.F.","year":"1992","unstructured":"Kane J.F.; Violand B.N.; Curran D.F.; Staten N.R.; Duffin K.L.; Bogosian G.; Novel in-frame two codon translational hop dur-ing synthesis of bovine placental lactogen in a recombinant strain of Escherichia coli. Nucleic Acids Res 1992,20(24),6707-6712","journal-title":"Nucleic Acids Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/10826060701774312","volume":"38","author":"Redwan E.R.M.","year":"2007","unstructured":"Redwan E.R.M.; Matar S.M.; El-Aziz G.A.; Serour E.A.; Synthesis of the human insulin gene: Protein expression, scaling up and bioactivity. Prep Biochem Biotechnol 2007,38(1),24-39","journal-title":"Prep Biochem Biotechnol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1006\/prep.2000.1203","volume":"18","author":"Dieci G.","year":"2000","unstructured":"Dieci G.; Bottarelli L.; Ballabeni A.; Ottonello S.; tRNA-assisted overproduction of eukaryotic ribosomal proteins. Protein Expr Purif 2000,18(3),346-354","journal-title":"Protein Expr Purif"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4014\/jmb.1412.12079","volume":"25","author":"Baeshen M.N.","year":"2015","unstructured":"Baeshen M.N.; Al-Hejin A.M.; Bora R.S.; Production of biopharmaceuticals in E. coli: Current scenario and future perspectives. J Microbiol Biotechnol 2015,25(7),953-962","journal-title":"J Microbiol Biotechnol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1128\/JB.00529-07","volume":"189","author":"Baker C.S.","year":"2007","unstructured":"Baker C.S.; E\u00f6ry L.A.; Yakhnin H.; Mercante J.; Romeo T.; Babitzke P.; CsrA inhibits translation initiation of Escherichia coli hfq by binding to a single site overlapping the Shine-Dalgarno sequence. J Bacteriol 2007,189(15),5472-5481","journal-title":"J Bacteriol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1128\/MMBR.69.1.101-123.2005","volume":"69","author":"Laursen B.S.","year":"2005","unstructured":"Laursen B.S.; S\u00f8rensen H.P.; Mortensen K.K.; Sperling-Petersen H.U.; Initiation of protein synthesis in bacteria. Microbiol Mol Biol Rev 2005,69(1),101-123","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0378-1119(00)00550-3","volume":"263","author":"Stenstr\u00f6m C.M.","year":"2001","unstructured":"Stenstr\u00f6m C.M.; Jin H.; Major L.L.; Tate W.P.; Isaksson L.A.; Codon bias at the 3\u2032-side of the initiation codon is correlated with translation initiation efficiency in Escherichia coli. Gene 2001,263(1-2),273-284","journal-title":"Gene"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bbrc.2007.02.127","volume":"356","author":"Park Y.S.","year":"2007","unstructured":"Park Y.S.; Seo S.W.; Hwang S.; Design of 5\u2032-untranslated region variants for tunable expression in Escherichia coli. Biochem Biophys Res Commun 2007,356(1),136-141","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1038\/srep04515","volume":"4","author":"Seo S.W.","year":"2014","unstructured":"Seo S.W.; Yang J.S.; Cho H.S.; Predictive combinatorial design of mRNA translation initiation regions for systematic optimization of gene expression levels. Sci Rep 2014,4(1),4515","journal-title":"Sci Rep"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.biotechadv.2011.09.013","volume":"30","author":"Chen R.","year":"2012","unstructured":"Chen R.; Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol Adv 2012,30(5),1102-1107","journal-title":"Biotechnol Adv"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.bbagrm.2013.01.012","volume":"1829","author":"Iost I.","year":"2013","unstructured":"Iost I.; Bizebard T.; Dreyfus M.; Functions of DEAD-box proteins in bacteria: Current knowledge and pending questions. Biochim Biophys Acta Gene Regul Mech 2013,1829(8),866-877","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/72464","volume":"7","author":"Linder P.","year":"2000","unstructured":"Linder P.; Daugeron M.C.; Are DEAD-box proteins becoming respectable helicases? Nat Struct Biol 2000,7(2),97-99","journal-title":"Nat Struct Biol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0168-1656(98)00073-X","volume":"63","author":"C\u00e9sar S\u00e1nchez J.","year":"1998","unstructured":"C\u00e9sar S\u00e1nchez J.; Padr\u00f3n G.; Santana H.; Herrera L.; Elimination of an HuIFN\u03b12b readthrough species, produced in Esch-erichia coli, by replacing its natural translational stop signal. J Biotechnol 1998,63(3),179-186","journal-title":"J Biotechnol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0092-8674(87)90433-8","volume":"48","author":"Newbury S.F.","year":"1987","unstructured":"Newbury S.F.; Smith N.H.; Robinson E.C.; Hiles I.D.; Higgins C.F.; Stabilization of translationally active mRNA by prokaryot-ic REP sequences. Cell 1987,48(2),297-310","journal-title":"Cell"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/j.1460-2075.1995.tb06985.x","volume":"14","author":"Poole E.S.","year":"1995","unstructured":"Poole E.S.; Brown C.M.; Tate W.P.; The identity of the base following the stop codon determines the efficiency of in vivo translational termination in Escherichia coli. EMBO J 1995,14(1),151-158","journal-title":"EMBO J"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0378-1119(89)90470-8","volume":"85","author":"Brinkmann U.","year":"1989","unstructured":"Brinkmann U.; Mattes R.E.; Buckel P.; High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product. Gene 1989,85(1),109-114","journal-title":"Gene"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1128\/mr.53.3.273-298.1989","volume":"53","author":"Parker J.","year":"1989","unstructured":"Parker J.; Errors and alternatives in reading the universal genetic code. Microbiol Rev 1989,53(3),273-298","journal-title":"Microbiol Rev"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0006-291X(88)81117-3","volume":"155","author":"Seetharam R.","year":"1988","unstructured":"Seetharam R.; Heeren R.A.; Wong E.Y.; Mistranslation in IGF-1 during over-expression of the protein in Escherichia coli using a synthetic gene containing low frequency codons. Biochem Biophys Res Commun 1988,155(1),518-523","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1006\/jmbi.1996.0524","volume":"262","author":"Calderone T.L.","year":"1996","unstructured":"Calderone T.L.; Stevens R.D.; Oas T.G.; High-level misincorporation of lysine for arginine at AGA codons in a fusion pro-tein expressed in Escherichia coli. J Mol Biol 1996,262(4),407-412","journal-title":"J Mol Biol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1128\/AEM.01901-10","volume":"77","author":"Fisher A.C.","year":"2011","unstructured":"Fisher A.C.; Haitjema C.H.; Guarino C.; Production of secretory and extracellular N-linked glycoproteins in Esche-richia coli. Appl Environ Microbiol 2011,77(3),871-881","journal-title":"Appl Environ Microbiol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.drudis.2013.11.008","volume":"19","author":"Overton T.W.","year":"2014","unstructured":"Overton T.W.; Recombinant protein production in bacterial hosts. Drug Discov Today 2014,19(5),590-601","journal-title":"Drug Discov Today"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/biot.200500051","volume":"1","author":"Graumann K.","year":"2006","unstructured":"Graumann K.; Premstaller A.; Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 2006,1(2),164-186","journal-title":"Biotechnol J"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40199-016-0156-7","volume":"24","author":"Fayaz S.","year":"2016","unstructured":"Fayaz S.; Fard-Esfahani P.; Golkar M.; Allahyari M.; Sadeghi S.; Expression, purification and biological activity assess-ment of romiplostim biosimilar peptibody. Daru 2016,24(1),18","journal-title":"Daru"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00253-011-3513-y","volume":"92","author":"Basu A.","year":"2011","unstructured":"Basu A.; Li X.; Leong S.S.J.; Refolding of proteins from inclusion bodies: Rational design and recipes. Appl Microbiol Biotechnol 2011,92(2),241-251","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.tibtech.2006.02.007","volume":"24","author":"Ventura S.","year":"2006","unstructured":"Ventura S.; Villaverde A.; Protein quality in bacterial inclusion bodies. Trends Biotechnol 2006,24(4),179-185","journal-title":"Trends Biotechnol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11010-007-9603-6","volume":"307","author":"Sahdev S.","year":"2007","unstructured":"Sahdev S.; Khattar S.K.; Saini K.S.; Production of active eukaryotic proteins through bacterial expression systems: A re-view of the existing biotechnology strategies. Mol Cell Biochem 2007,307(1-2),249-264","journal-title":"Mol Cell Biochem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10295-011-1082-9","volume":"39","author":"Huang C.J.","year":"2012","unstructured":"Huang C.J.; Lin H.; Yang X.; Industrial production of recombinant therapeutics in Escherichia coli and its recent ad-vancements. J Ind Microbiol Biotechnol 2012,39(3),383-399","journal-title":"J Ind Microbiol Biotechnol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/b93995","volume":"89","author":"Fahnert B.","year":"2004","unstructured":"Fahnert B.; Lilie H.; Neubauer P.; Inclusion bodies: Formation and utilisation. Adv Biochem Eng Biotechnol 2004,89,93-142","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bit.260360102","volume":"36","author":"Jensen E.B.","year":"1990","unstructured":"Jensen E.B.; Carlsen S.; Production of recombinant human growth hormone in Escherichia coli: Expression of different precursors and physiological effects of glucose, acetate, and salts. Biotechnol Bioeng 1990,36(1),1-11","journal-title":"Biotechnol Bioeng"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/prep.1996.0678","volume":"9","author":"Vasina J.A.","year":"1997","unstructured":"Vasina J.A.; Baneyx F.; Expression of aggregation-prone recombinant proteins at low temperatures: A comparative study of the Escherichia coli cspA and tac promoter systems. Protein Expr Purif 1997,9(2),211-218","journal-title":"Protein Expr Purif"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2004.11.003","volume":"23","author":"Mergulh\u00e3o F.J.M.","year":"2005","unstructured":"Mergulh\u00e3o F.J.M.; Summers D.K.; Monteiro G.A.; Recombinant protein secretion in Escherichia coli. Biotechnol Adv 2005,23(3),177-202","journal-title":"Biotechnol Adv"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00253-004-1559-9","volume":"64","author":"Choi J.H.","year":"2004","unstructured":"Choi J.H.; Lee S.Y.; Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol 2004,64(5),625-635","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1073\/pnas.95.6.2773","volume":"95","author":"Joly J.C.","year":"1998","unstructured":"Joly J.C.; Leung W.S.; Swartz J.R.; Overexpression of Escherichia coli oxidoreductases increases recombinant insulin-like growth factor-I accumulation. Proc Natl Acad Sci 1998,95(6),2773-2777","journal-title":"Proc Natl Acad Sci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s004490100267","volume":"24","author":"Yim S.","year":"2001","unstructured":"Yim S.; Jeong K.; Chang H.; Lee S.; High-level secretory production of human granulocyte-colony stimulating factor by fed-batch culture of recombinant Escherichia coli. Bioprocess Biosyst Eng 2001,24(4),249-254","journal-title":"Bioprocess Biosyst Eng"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2859-8-9","volume":"8","author":"Kolaj O.","year":"2009","unstructured":"Kolaj O.; Spada S.; Robin S.; Wall J.G.; Use of folding modulators to improve heterologous protein production in Esche-richia coli. Microb Cell Fact 2009,8(1),9","journal-title":"Microb Cell Fact"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-0-387-76643-0_17","author":"Reilly D.E.","year":"2010","unstructured":"Reilly D.E.; Yansura D.G.;  In: Current trends in monoclonal antibody development and manufacturing 2010,295-308","journal-title":"In: Current trends in monoclonal antibody development and manufacturing"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1006\/prep.2001.1506","volume":"23","author":"Mavrangelos C.","year":"2001","unstructured":"Mavrangelos C.; Thiel M.; Adamson P.J.; Increased yield and activity of soluble single-chain antibody fragments by combining high-level expression and the Skp periplasmic chaperonin. Protein Expr Purif 2001,23(2),289-295","journal-title":"Protein Expr Purif"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1073\/pnas.0937838100","volume":"100","author":"DeLisa M.P.","year":"2003","unstructured":"DeLisa M.P.; Tullman D.; Georgiou G.; Folding quality control in the export of proteins by the bacterial twin-arginine trans-location pathway. Proc Natl Acad Sci 2003,100(10),6115-6120","journal-title":"Proc Natl Acad Sci"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1006\/prep.2001.1508","volume":"23","author":"Jeong K.J.","year":"2001","unstructured":"Jeong K.J.; Lee S.Y.; Secretory production of human granulocyte colony-stimulating factor in Escherichia coli. Protein Expr Purif 2001,23(2),311-318","journal-title":"Protein Expr Purif"},{"key":"ref=89","first-page":"40","volume":"7","author":"M\u00fccke M.","year":"2009","unstructured":"M\u00fccke M.; Ostendorp R.; Leonhartsberger S.E.; coli secretion technologies enable production of high yields of active human antibody fragments. Bioprocess Int 2009,7(8),40-47","journal-title":"Bioprocess Int"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/187220810790069550","volume":"4","author":"Yoon S.","year":"2010","unstructured":"Yoon S.; Kim S.; Kim J.; Secretory production of recombinant proteins in Escherichia coli. Recent Pat Biotechnol 2010,4(1),23-29","journal-title":"Recent Pat Biotechnol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00253-002-1156-8","volume":"60","author":"Shokri A.","year":"2003","unstructured":"Shokri A.; Sand\u00e9n A.; Larsson G.; Cell and process design for targeting of recombinant protein into the culture medium of Escherichia coli. Appl Microbiol Biotechnol 2003,60(6),654-664","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1128\/AEM.64.8.2869-2874.1998","volume":"64","author":"Yang J.","year":"1998","unstructured":"Yang J.; Moyana T.; MacKenzie S.; Xia Q.; Xiang J.; One hundred seventy-fold increase in excretion of an FV fragment-tumor necrosis factor alpha fusion protein (sFV\/TNF-alpha) from Escherichia coli caused by the synergistic effects of glycine and triton X-100. Appl Environ Microbiol 1998,64(8),2869-2874","journal-title":"Appl Environ Microbiol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00253-001-0889-0","volume":"58","author":"Shokri A.","year":"2002","unstructured":"Shokri A.; Sand\u00e9n A.M.; Larsson G.; Growth rate-dependent changes in Escherichia coli membrane structure and protein leakage. Appl Microbiol Biotechnol 2002,58(3),386-392","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jbiotec.2008.05.002","volume":"135","author":"B\u00e4cklund E.","year":"2008","unstructured":"B\u00e4cklund E.; Reeks D.; Markland K.; Weir N.; Bowering L.; Larsson G.; Fedbatch design for periplasmic product retention in Escherichia coli. J Biotechnol 2008,135(4),358-365","journal-title":"J Biotechnol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/337525a0","volume":"337","author":"Capon D.J.","year":"1989","unstructured":"Capon D.J.; Chamow S.M.; Mordenti J.; Designing CD4 immunoadhesins for AIDS therapy. Nature 1989,337(6207),525-531","journal-title":"Nature"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tibtech.2014.11.001","volume":"33","author":"Levin D.","year":"2015","unstructured":"Levin D.; Golding B.; Strome S.E.; Sauna Z.E.; Fc fusion as a platform technology: Potential for modulating immunogenici-ty. Trends Biotechnol 2015,33(1),27-34","journal-title":"Trends Biotechnol"},{"key":"ref=97","first-page":"43","volume":"23","author":"Zhang L.","year":"2000","unstructured":"Zhang L.; Ma W.; Da J.; Mycobacterium vaccae influences the kinetics of Th1\/Th2 cells and expression of iNOS in a ma-rine model of experimental tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 2000,23(1),43-46","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3109\/07388551.2016.1163323","volume":"37","author":"Soleimanpour S.","year":"2017","unstructured":"Soleimanpour S.; Hassannia T.; Motiee M.; Amini A.A.; Rezaee S.A.R.; Fc\u03b31 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties. Crit Rev Biotechnol 2017,37(3),371-392","journal-title":"Crit Rev Biotechnol"}],"container-title":["Recent Patents on Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872208317666230503094451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216459\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872208317666230503094451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T13:49:04Z","timestamp":1705672144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216459\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872208317666230503094451","relation":{},"ISSN":["1872-2083"],"issn-type":[{"value":"1872-2083","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}